CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane Meeting Abstract
| Authors: | O'Shaughnessy, J.; Piccart, M.; Schwartzberg, L.; Cortes, J.; Harbeck, N.; Im, S. A.; Rugo, H.; Untch, M.; Yardley, D.; Bondarenko, I.; Dieras, V.; Pegram, M.; Kroll, S.; O'Connell, J.; Vacirca, J.; Wei, T.; Tang, K.; Seidman, A. |
| Abstract Title: | CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500104 |
| DOI: | 10.1158/1538-7445.Sabcs19-ot1-08-09 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-08-09 -- Source: Wos |
